{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:59:29Z","timestamp":1762001969099,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Public Research Agency of the Republic of Slovenia","doi-asserted-by":"publisher","award":["P3-0343"],"award-info":[{"award-number":["P3-0343"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ymgmr.2021.100779","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:00:51Z","timestamp":1624690851000},"page":"100779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) \u2013 Case series"],"prefix":"10.1016","volume":"28","author":[{"given":"Mojca","family":"Zerjav Tansek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Kodric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Klemencic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap Jan","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Drole Torkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Doric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alenka","family":"Koren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Avcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urh","family":"Groselj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2021.100779_bb0005","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgmr.2021.100779_bb0010","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","article-title":"Cumulative incidence rates of the mucopolysaccharidoses in Germany","volume":"28","author":"Baehner","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1651-2227.2007.00212.x","article-title":"A clinical study of 77 patients with mucopolysaccharidosis type II","volume":"96","author":"Schwartz","year":"2007","journal-title":"Acta. Paed."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0030","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the hunter outcome survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2016.05.003","article-title":"Molecular diagnosis of 65 families with mucopolysaccharidosis type II (hunter syndrome) characterized by 16 novel mutations in the IDS gene: genetic, pathological, and structural studies on iduronate-2-sulfatase","volume":"118","author":"Kosuga","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Gen. Metab."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0045","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/ijms21082975","article-title":"Intravenous enzyme replacement therapy in Mucopolysaccharidoses: clinical effectiveness and limitations","volume":"21","author":"Parini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0050","first-page":"6","article-title":"Hematopoietic stem cell therapy and novel approaches for Mucopolysaccharidoses","volume":"1","author":"Edwards","year":"2014","journal-title":"J. Blood. Disord."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0055","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with Mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood. Marrow. Transplant."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0060","series-title":"Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual","first-page":"77","article-title":"Screening for Mucopolysaccharidoses by analysis of urinary glycosaminoglycans","author":"Dembure","year":"1991"},{"key":"10.1016\/j.ymgmr.2021.100779_bb0065","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1012763026526","article-title":"A fluorimetric enzyme assay for the diagnosis of MPS II (hunter disease)","volume":"24","author":"Voznyi","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0070","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cge.12927","article-title":"Genotype-phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II","volume":"91","author":"Dvorakova","year":"2017","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0075","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10545-006-0440-7","article-title":"Effect of hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis","volume":"29","author":"Sukegawa-Hayasaka","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0080","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13023-019-1202-6","article-title":"Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases","volume":"14","author":"Sampayo-Cordero","year":"2019","journal-title":"Orphanet. J. Rare. Dis."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100779_bb0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2013.4915","article-title":"Survival and psychomotor development with early betaine treatment in patients with severe methylenetetrahydrofolate reductase deficiency","volume":"71","author":"Diekman","year":"2014","journal-title":"JAMA neurology."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S0098858800009205","article-title":"Limits of guardian treatment refusal: a reasonableness standard","volume":"9","author":"Veatch","year":"1984","journal-title":"Am. J. Law. Med."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13023-019-1027-3","article-title":"An online survey on burden of illness among families with post-stem cell transplant mucopolysaccharidosis type I children in the United States","volume":"14","author":"Conner","year":"2019","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0105","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00246-013-0653-0","article-title":"Massive accumulation of glycosaminoglycans in the aortic valve of a patient with hunter syndrome during enzyme replacement therapy","volume":"34","author":"Sato","year":"2013","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0110","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"HOS investigators, mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the hunter outcome survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0115","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/gim.2017.30","article-title":"Treatment of mucopolysaccharidosis type II (hunter syndrome): results from a systematic evidence review","volume":"19","author":"Bradley","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"12","key":"10.1016\/j.ymgmr.2021.100779_bb0125","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/bloodadvances.2020001708","article-title":"Hurdles in treating hurler disease: potential routes to achieve a \u201creal\u201d cure","volume":"4","author":"van den Broek","year":"2020","journal-title":"Blood Adv.."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0130","first-page":"100630","article-title":"Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (hunter syndrome): contribution of genotype to cognitive developmental course","volume":"24","author":"Seo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"21","key":"10.1016\/j.ymgmr.2021.100779_bb0135","article-title":"The natural history of neurocognition in MPS disorders: a review","volume":"S1096-7192","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-017-0712-3","article-title":"Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0145","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","article-title":"Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series","volume":"37","author":"Lampe","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe hunter syndrome\u2014an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0155","first-page":"99","article-title":"Enzyme replacement therapy in Mucopolysaccharidosis II patients under 1 year of age","volume":"14","author":"Lampe","year":"2014","journal-title":"JIMD. Rep."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0160","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for Mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood. Marrow. Transplant."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0165","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymgme.2014.11.002","article-title":"Activities of daily living in patients with hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation","volume":"114","author":"Tanjuakio","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0185","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fped.2019.00433","article-title":"Hematopoietic stem cell transplantation in inborn errors of metabolism","volume":"7","author":"Tan","year":"2019","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0190","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/bjh.13059","article-title":"Transplantation in inborn errors of metabolism: current considerations and future perspectives","volume":"167","author":"Boelens","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0195","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13052-018-0565-y","article-title":"Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches","volume":"44","author":"Fraldi","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0200","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0205","first-page":"256","article-title":"Expanded newborn screening program in Slovenia using tandem mass spectrometry and confirmatory next generation sequencing genetic testing","volume":"59","author":"Lampret","year":"2020","journal-title":"Zdr. Varst."},{"key":"10.1016\/j.ymgmr.2021.100779_bb0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/ijns7010015","article-title":"Neonatal screening in europe revisited: an ISNS perspective on the current state and developments since 2010","volume":"7","author":"Loeber","year":"2021","journal-title":"Int. J. Neonatal. Screen."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921000732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921000732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:51:28Z","timestamp":1762001488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426921000732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":40,"alternative-id":["S2214426921000732"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100779","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) \u2013 Case series","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100779"}}